Poltreg S.A. (WSE:PTG)
Poland · Delayed Price · Currency is PLN 25.30
-0.30 (-1.17%)
Nov 14, 2025, 5:00 PM CET
Poltreg Company Description
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases.
It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis.
The company was incorporated in 2016 and is based in Gdansk, Poland.
Poltreg S.A.
| Country | Poland |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Piotr Trzonkowsk |
Contact Details
Address: ul. Botaniczna 20 Gdansk, 80-298 Poland | |
| Phone | 48 512 53 24 01 |
| Website | poltreg.tech |
Stock Details
| Ticker Symbol | PTG |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLPLTRG00038 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Piotr Trzonkowsk | President of the Management Board |
| Paulina Kocenko-Merks | Chief Financial Officer and Member of Management Board |
| Mariusz Jablonski | Member of the Management Board |
| Kamilla Agnieszka Bok | Director of Operations |